Table 2.
Study Period | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | Statistics | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
AMC R (%) b | Outpatient | 12.16 | 17.57 | 31.08 | 60.81 | 28.38 | 37.84 | 63.51 | 66.22 | 75.68 | 62.16 | n.s. (p = 0.499) |
Inpatient | 32.35 | 37.50 | 47.17 | 59.74 | 56.08 | 63.23 | 54.44 | 56.56 | 53.13 | 49.03 | ||
CRO R (%) | Outpatient | 4.05 | 4.11 | 11.94 | 27.72 | 31.58 | 38.14 | 25.41 | 26.15 | 17.76 | 24.10 | P = 0.0071 |
Inpatient | 16.18 | 23.21 | 33.02 | 48.70 | 47.30 | 47.10 | 41.42 | 40.27 | 33.75 | 30.97 | ||
GEN R (%) | Outpatient | 10.81 | 13.70 | 20.90 | 10.89 | 10.53 | 11.34 | 15.57 | 18.46 | 15.79 | 17.47 | n.s. (p = 0.32) |
Inpatient | 16.18 | 14.29 | 16.04 | 11.69 | 20.27 | 14.19 | 10.06 | 23.53 | 18.75 | 18.06 | ||
CIP R (%) | Outpatient | 8.11 | 10.96 | 11.94 | 23.76 | 30.26 | 18.56 | 27.05 | 37.69 | 26.97 | 37.35 | P < 0.0001 |
Inpatient | 35.29 | 26.79 | 45.28 | 62.34 | 56.76 | 50.97 | 52.07 | 43.89 | 44.38 | 40.00 | ||
SXT R (%) | Outpatient | 28.38 | 35.62 | 32.84 | 45.54 | 50.00 | 38.14 | 59.02 | 59.23 | 57.24 | 57.23 | P = 0.0025 |
Inpatient | 55.88 | 50.00 | 50.94 | 74.68 | 68.24 | 61.94 | 66.27 | 64.71 | 62.50 | 65.16 |
a Values in italics represent the lowest (baseline) resistance levels, boldface (peak) values correspond to the highest resistance levels in the study period; b Corresponding to P. mirabilis susceptibility; n.s.: not significant.